Elutia sells SimpliDerm business to Cellution Biologics for up to $11 million
ELUT•Proceeds shift focus to NXT-41x
The divestiture shifts resources toward NXT-41x, with FDA clearance targeted for the first half of 2027.
Proceeds support funding through the first full year of the planned NXT-41x commercial launch in 2028.
SimpliDerm sale completed for cash and contingent payments
Elutia closed the sale of its SimpliDerm human acellular dermal matrix business to Cellution Biologics for up to $11 million.
- Elutia received $8 million in cash at closing, subject to customary inventory adjustments and transaction expenses.
- The deal includes up to $3 million of contingent milestone payments over the next 18 months.
